The novel hybrid antitumor compound premithramycinone H provides indirect evidence for a tricyclic intermediate of the biosynthesis of the aureolic acid antibiotic mithramycin

Felipe Lombó, Eva Künzel, Laura Prado, Alfredo F. Braña, Kai U. Bindseil, Jürgen Frevert, Dan Bearden, Carmen Méndez, José A. Salas, Jürgen Rohr

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Gene recombination experiments are not only useful for the generation of novel hybrid natural products, but can also be helpful in intercepting unstable biosynthetic intermediates to allow conclusions to be made about their structures. Premithramycinone H (1), a biologically active hybrid which results from a mixture of mithramycin and tetracenomycin biosynthetic genes, is a good example of this strategy.

Original languageEnglish
Pages (from-to)796-799
Number of pages4
JournalAngewandte Chemie - International Edition
Volume39
Issue number4
DOIs
StatePublished - Feb 18 2000

Keywords

  • Antibiotics
  • Antitumor agents
  • Biosynthesis
  • Hybrid natural products
  • Polyketides

ASJC Scopus subject areas

  • Catalysis
  • Chemistry (all)

Fingerprint

Dive into the research topics of 'The novel hybrid antitumor compound premithramycinone H provides indirect evidence for a tricyclic intermediate of the biosynthesis of the aureolic acid antibiotic mithramycin'. Together they form a unique fingerprint.

Cite this